Advertisement

Treatment of solar lentigines

      Therapy for solar lentigines is diverse but can be divided into two broad categories: physical therapy and topical therapy. Physical therapies are frequently used with excellent clinical success rates, but this has to be balanced against associated side effects and recurrence rates with certain therapies. A range of topical therapies have been used and, more recently, fixed combinations of topical agents have been investigated. The Pigmentary Disorders Academy undertook to evaluate the clinical efficacy of the different treatments of solar lentigines in order to generate a consensus statement on their management. Clinical papers published during the past 20 years were identified through MEDLINE searches and methodology and outcome were assessed according to guidelines adapted from the US Preventive Services Task Force (USPSTF) on health care. The consensus of the group was that first-line therapy for solar lentigines was ablative therapy with cryotherapy. Although no large-scale studies have been completed, there is also good evidence to suggest that lasers are an effective treatment. An alternative to ablative therapy is topical therapy and there is good evidence to support the use of a fixed double combination, as well as retinoids, such as adapalene and tretinoin. Topical therapy can also be considered as maintenance therapy after the primary therapy has been applied. Because of the diversity of scoring systems used in the assessment of treatment outcome, the group recommends the development of treatment guidelines.

      Abbreviations used:

      4HA (4-hydroxyanisole), HQ (hydroquinone), IPL (intense pulsed light), PDA (Pigmentary Disorders Academy), RA (retinoic acid (tretinoin)), TCA (trichloroacetic acid), VLP (Versapulse long-pulse [Nd:YAG 532-nm laser]), VQS (Versapulse Q-switched [Nd:YAG 532-nm laser])
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Freedberg I.M.
        • Eisen A.Z.
        • Wolff K.
        • Austen K.F.
        • Goldsmith L.A.
        • Katz S.I.
        Fitzpatrick's dermatology in general medicine.
        5th ed. McGraw-Hill, New York1999
        • Ortonne J.-P.
        Pigmentary changes of the ageing skin.
        Br J Dermatol. 1990; 122: 21-28
        • Hexsel D.M.
        • Mazzuco R.
        • Bohn J.
        • Borges J.
        • Gobbato D.O.
        Clinical comparative study between cryotherapy and local dermabrasion for the treatment of solar lentigo on the back of hands.
        Dermatol Surg. 2000; 26: 457-462
        • Gage A.A.
        • Meenaghan M.A.
        • Natiella J.R.
        • Green Jr., G.W.
        Sensitivity of pigmented mucosa and skin to freezing injury.
        Cryobiology. 1979; 16: 348-361
        • Almond-Roesler B.
        • Zouboulis C.C.
        Successful treatment of solar lentigines by brief gentle cryosurgery using a Kryomed® device.
        Br J Dermatol. 2000; 143: 216-218
        • Zouboulis C.C.
        • Rosenberger A.D.
        • Adler Y.
        • Orfanos C.E.
        Treatment of solar lentigo with cryosurgery.
        Acta Derm Venereol. 1999; 79: 489-490
        • Stratigos A.J.
        • Dover J.S.
        • Arndt K.A.
        Laser treatment of pigmented lesions–2000. How far have we gone?.
        Arch Dermatol. 2000; 136: 915-921
        • Kopera D.
        • Hohenleutner U.
        • Landthaler M.
        Quality-switched ruby laser treatment of solar lentigines and Becker's nevus: a histopathological and immunohistochemical study.
        Dermatology. 1997; 194: 338-343
        • Rosenbach A.
        Treatment of medium-brown solar lentigines using an alexandrite laser designed for hair reduction.
        Arch Dermatol. 2002; 138: 547-548
        • Chan H.H.
        • Fung W.K.K.
        • Ying S.-Y.
        • Kono T.
        An in vivo trial comparing the use of different types of 532 nm Nd:YAG lasers in the treatment of facial lentigines in Oriental patients.
        Dermatol Surg. 2000; 26: 743-749
        • Rashid T.
        • Hussain I.
        • Haider M.
        • Haroon T.S.
        Laser therapy of freckles and lentigines with quasi-continuous frequency-doubled, Nd:YAG (532 nm) laser in Fitzpatrick skin type IV: a 24-month follow-up.
        J Cosmet & Laser Ther. 2002; 4: 81-85
        • Stern R.S.
        • Dover J.S.
        • Levin J.A.
        • Arndt K.A.
        Laser therapy versus cryotherapy of lentigines: a comparative trial.
        J Am Acad Dermatol. 1994; 30: 985-987
        • Todd M.M.
        • Rallis T.M.
        • Gerwels J.W.
        • Hata T.R.
        A comparison of 3 lasers and liquid nitrogen in the treatment of solar lentigines.
        Arch Dermatol. 2000; 136: 841-846
        • Li Y.-T.
        • Yang K.-C.
        Comparison of the frequency-doubled Q-switched Nd:YAG laser and 35% trichloroacetic acid for the treatment of face lentigines.
        Dermatol Surg. 1999; 25: 202-204
        • Kawada A.
        • Shiraishi H.
        • Asai M.
        • Kameyama H.
        • Sangen Y.
        • Aragane Y.
        • et al.
        Clinical improvement of solar lentigines and ephelides with an intense pulsed light source.
        Dermatol Surg. 2002; 28: 504-508
        • Kawada A.
        • Asai M.
        • Kameyama H.
        • Sangen Y.
        • Aragane Y.
        • Tezuka T.
        • et al.
        Videomicroscopic and histopathological investigation of intense pulsed light therapy for solar lentigines.
        J Dermatol Sci. 2002; 29: 91-96
        • Fulton Jr., J.E.
        Dermabrasion, chemabrasion, and laser abrasion; historical perspectives, modern dermabrasion techniques, and future trends.
        Dermatol Surg. 1996; 22: 619-628
        • Cotellessa C.
        • Peris K.
        • Fargnoli M.C.
        • Mordenti C.
        • Giacomello R.S.
        • Chimenti S.
        Microabrasion versus microabrasion followed by 15% trichloroacetic acid for treatment of cutaneous hyperpigmentation in adult females.
        Dermatol Surg. 2003; 29: 352-356
        • Newman N.
        • Newman A.
        • Moy L.
        • Babapour R.
        • Harris A.G.
        • Moy R.L.
        Clinical improvement of photoaged skin with 50% glycolic acid.
        Dermatol Surg. 1996; 22: 455-460
        • Collins P.S.
        Trichloroacetic acid peels revisited.
        J Dermatol Surg Oncol. 1989; 15: 933-940
        • Monheit G.D.
        The Jessner's + TCA peel: a medium-depth chemical peel.
        J Dermatol Surg Oncol. 1989; 15: 945-950
        • Swinehart J.M.
        Salicylic acid ointment peeling of the hands and forearms: effective nonsurgical removal of pigmented lesions and actinic damage.
        Dermatol Surg Oncol. 1992; 18: 495-498
        • Kligman D.
        • Kligman A.M.
        Salicylic acid peels for the treatment of photoaging.
        Dermatol Surg. 1988; 24: 325-328
        • Cook K.K.
        • Cook W.R.
        Chemical peel of nonfacial skin using glycolic acid gel augmented with TCA and neutralized based on visual staging.
        Dermatol Surg. 2000; 26: 994-999
        • Lugo-Janer A.
        • Lugo-Somolinos A.
        • Sanchez J.L.
        Comparison of trichloroacetic acid solution and cryosurgery in the treatment of solar lentigines.
        Int J Dermatol. 2003; 42: 829-831
        • Palumbo A.
        • d'Ischia M.
        • Misuraca G.
        • Prota G.
        Mechanism of inhibition of melanogenesis by hydroquinone.
        Biochem Biophys Acta. 1991; 1073: 85-90
        • Romero C.
        • Aberdam E.
        • Larnier C.
        • Ortonne J.P.
        Retinoic acid as modulator of UVB-induced melanocyte differentiation. Involvement of the melanogenic enzymes expression.
        J Cell Sci. 1994; 107: 1095-1103
        • Petit L.
        • Piérard G.E.
        Analytic quantification of solar lentigines lightening by a 2% hydroquinone-cyclodextrin formulation.
        J Eur Acad Dermatol Venereol. 2003; 17: 546-549
        • Weinstein G.D.
        • Nigra T.P.
        • Pochi P.E.
        • Savin R.C.
        • Allan A.
        • Benik K.
        • et al.
        Topical tretinoin for treatment of photodamaged skin. A multicenter study.
        Arch Dermatol. 1991; 127: 659-665
        • Rafal E.S.
        • Griffiths C.E.
        • Ditre C.M.
        • Finkel L.J.
        • Hamilton T.A.
        • Ellis C.N.
        • et al.
        Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage.
        N Engl J Med. 1992; 326: 368-374
        • Phillips T.J.
        • Gottlieb A.B.
        • Leyden J.J.
        • Lowe N.J.
        • Lew-Kaya D.A.
        • Sefton J.
        • et al.
        Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month, multicenter, randomized trial.
        Arch Dermatol. 2002; 138: 1486-1493
        • Kang S.
        • Goldfarb M.T.
        • Weiss J.S.
        • Metz R.D.
        • Hamilton T.A.
        • Voorhees J.J.
        • et al.
        Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial.
        J Am Acad Dermatol. 2003; 49: 83-90
        • Yoshimura K.
        • Harii K.
        • Aoyama T.
        • Iga T.
        Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals.
        Plast Reconstr Surg. 2000; 105: 1097-1108
        • Jarratt M.
        Mequinol 2%/ tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines.
        Cutis. 2004; 74: 319-322
        • Fleischer Jr., A.B.
        • Schwartzel E.H.
        • Colby S.I.
        • Altman D.J.
        • the Depigmenting Solution Study Group
        The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies.
        J Am Acad Dermatol. 2000; 42: 459-467
        • Ortonne J.-P.
        • Camacho F.
        • Wainwright N.
        • Bergfelt L.
        • Westerhof W.
        • Roseeuw D.
        Safety and efficacy of combined use of 4-hydroxyanisole (mequinol) 2%/tretinoin 0.01% solution and sunscreen in solar lentigines.
        Cutis. 2004; 74: 261-264
        • Williams H.C.
        Dermatology.
        in: Stevens A. Raftery J. Health care needs assessment. Second series. Radcliffe Medical Press, Oxford (UK)1997: 340